{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/mi-secondary-prevention/goals-outcome-measures/qof-indicators/","result":{"pageContext":{"chapter":{"id":"02b0b701-c0f0-542f-b958-8d30a81301fc","slug":"qof-indicators","fullItemName":"QOF indicators","depth":2,"htmlHeader":"<!-- begin field 404576e1-0b2f-4478-8374-e6c5a062c7c7 --><h2>QOF indicators</h2><!-- end field 404576e1-0b2f-4478-8374-e6c5a062c7c7 -->","summary":null,"htmlStringContent":"<!-- begin item 57d0ec5b-2211-49b5-bbc4-6a5696cc8718 --><!-- begin field 6a7e80b9-bc69-4e9b-beea-586713dee588 --><p><strong>Table 1</strong><strong>. </strong>Indicators related to secondary prevention of coronary heart disease in the Quality and Outcomes Framework (QOF) of the General Medical Services (GMS) contract.</p><table><thead><tr><th colspan=\"1\"><p>Indicator</p></th><th colspan=\"1\"><p>Points</p></th><th colspan=\"1\"><p>Payment stages</p></th></tr></thead><tbody><tr><td colspan=\"3\"><strong>Secondary prevention of coronary heart disease (CHD)</strong></td></tr><tr><td colspan=\"1\">CHD001 The contractor establishes and maintains a register of patients with coronary heart disease</td><td colspan=\"1\">4</td><td colspan=\"1\">—</td></tr><tr><td colspan=\"1\">CHD002 The percentage of patients with coronary heart disease in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less</td><td colspan=\"1\">17</td><td colspan=\"1\">53–93%</td></tr><tr><td colspan=\"1\">CHD005 The percentage of patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken</td><td colspan=\"1\">7</td><td colspan=\"1\">56-96%</td></tr><tr><td colspan=\"1\">CHD007 The percentage of patients with coronary heart disease who have had influenza immunisation in the preceding 1 August to 31 March</td><td colspan=\"1\">7</td><td colspan=\"1\">56-96%</td></tr><tr><td colspan=\"3\"><strong>Smoking</strong></td></tr><tr><td colspan=\"1\">SMOK002 The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months</td><td colspan=\"1\">25</td><td colspan=\"1\">50–90%</td></tr><tr><td colspan=\"1\">SMOK003 The contractor supports patients who smoke in stopping smoking by a strategy which includes providing literature and offering appropriate therapy</td><td colspan=\"1\">2</td><td colspan=\"1\">—</td></tr><tr><td colspan=\"1\">SMOK004 The percentage of patients aged 15 or over who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 24 months</td><td colspan=\"1\">12</td><td colspan=\"1\">40–90%</td></tr><tr><td colspan=\"1\">SMOK005 The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months</td><td colspan=\"1\">25</td><td colspan=\"1\">56–96%</td></tr><tr><td colspan=\"3\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">BMA and NHS Employers, 2018</a>]</td></tr></tbody></table><!-- end field 6a7e80b9-bc69-4e9b-beea-586713dee588 --><!-- end item 57d0ec5b-2211-49b5-bbc4-6a5696cc8718 -->","topic":{"id":"10808f6c-5a83-5526-84e2-5998dee92475","topicId":"0b3a22ee-885a-43aa-8d4b-a290dc2afbcc","topicName":"MI - secondary prevention","slug":"mi-secondary-prevention","lastRevised":"Last revised in May 2020","chapters":[{"id":"6d17bc7f-3ed1-5a79-b4f4-8e9dc752c658","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a57b961c-8bba-5c02-8844-b6307b89222c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"dc552ddd-7106-5f5f-a7d9-4b2d6f80e1fa","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e9a32a50-5bdc-5fc0-8ecb-152881ffa7ad","slug":"changes","fullItemName":"Changes"},{"id":"d4c6dcc6-12c6-52a1-957d-47a931a225ec","slug":"update","fullItemName":"Update"}]},{"id":"8c06d36f-1d73-5741-981b-5ed3cc16b7c2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cd13560d-8bec-5902-9a9e-2ce26eaa9028","slug":"goals","fullItemName":"Goals"},{"id":"b9d35945-0a30-523a-9ded-6a2ea7f5a79a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5c84a4ff-a034-50b3-b1a3-7cfecfb1e65c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"02b0b701-c0f0-542f-b958-8d30a81301fc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f516bbb5-ea19-5f8f-be12-d8f550493156","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cf211bbf-df50-54c9-b204-ef227db8c62f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3ddc8181-0420-5ae4-8326-2d5ef700203a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f303e07d-da7d-5073-b00b-f3dd008f2594","slug":"definition","fullItemName":"Definition"},{"id":"45810734-c13c-5bbd-b314-88dcbfd54c57","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5488a58d-1964-5d60-a54e-a420fd0daeff","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b05c9d6f-fae2-5624-bc64-e5456fa46e84","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"2dd1d8e3-398b-5765-b249-43150874e311","fullItemName":"Management","slug":"management","subChapters":[{"id":"6854ca49-f0af-50f1-8fd3-a6bb900b4bc4","slug":"secondary-prevention","fullItemName":"Scenario: Secondary prevention"}]},{"id":"a4fb09c9-df2a-5800-954a-58fe23af6127","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e43e8d70-7611-5939-94cb-7cc18a3950a6","slug":"ace-inhibitors","fullItemName":"ACE inhibitors"},{"id":"0220c0cb-0802-5bfa-9d8b-f767f73dbea1","slug":"antiplatelet-treatments","fullItemName":"Antiplatelet treatments"},{"id":"a6c13387-db91-5f87-9795-c95a1be0a245","slug":"beta-blockers","fullItemName":"Beta blockers"},{"id":"064bc21b-4d02-5987-9c23-08b1ca8870d1","slug":"statins","fullItemName":"Statins"}]},{"id":"05c20737-02bb-500e-b3e6-0a506d19e727","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1ae6e3bc-f751-5c4b-a14d-09c72b74424e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a3e487f8-13d0-532b-b16f-d448106af2ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"03c8dfe8-3b8b-5c16-ab71-21f98aa13dcd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a1919ef1-18db-59ab-8c6d-7ef4d649f5d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3e57d884-d476-55de-a85c-a5e4e2001343","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e8c5059d-6ccf-58a3-bb80-1a8273c64c14","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bcfd412e-e461-5a99-a38f-a03a01873fa5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8c06d36f-1d73-5741-981b-5ed3cc16b7c2","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}